Comparison · NCT01189890-b697a792
Sitagliptin vs Glimepiride: Number of Participants Discontinuing Study Treatment Due to An AE
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sitagliptin vs Glimepiride: Number of Participants Discontinuing Study Treatment Due to An AE. Trial comparisons, record NCT01189890-b697a792. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01189890-b697a792
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0124 | 0.00424 | 0.036 | wilson | |
| Risk in group 2 | 0.0169 | 0.00661 | 0.0428 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0045 | -0.0316 | 0.0212 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.734 | 0.166 | 3.25 | log | |
| Odds ratio, group 1 over group 2 | 0.731 | 0.162 | 3.3 | log | |
| Number needed to treat, for one fewer participant with the outcome on Sitagliptin than on Glimepiride | 222 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sitagliptin | Sitagliptin phosphate 100 mg once daily (QD) or 50 mg QD | 3 | 241 | OG000 |
| Group 2 | Glimepiride | Glimepiride 1-6 mg QD | 4 | 236 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Discontinuing Study Treatment Due to An AE
- Description
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the~study treatment, whether or not considered related to the use of the treatment administered.
- Time frame
- Up to Week 30
- Population
- All randomized participants who received at least one dose of study treatment.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
- NCT number
- NCT01189890
- Phases
- PHASE3
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- sitagliptin phosphate, Glimepiride, Placebo to Sitagliptin, Placebo to Glimepiride
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2013-06-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01189890?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01189890-b697a792